深圳信立泰药业股份有限公司药品申请临床试验默示许可获受理

Core Viewpoint - Shenzhen Xinlitai Pharmaceutical Co., Ltd. has received implied permission for clinical trials of "SAL023 Injection," aimed at treating osteoporosis in postmenopausal women at high risk of fractures [1] Company Overview - Shenzhen Xinlitai Pharmaceutical Co., Ltd. was established in 1998 and is located in Shenzhen, primarily engaged in the pharmaceutical manufacturing industry [1] - The company has a registered capital of 11,148.16535 million RMB and a paid-in capital of 6,631.13804 million RMB [1] - The company has invested in 19 enterprises and participated in 5,000 bidding projects [1] - It holds 287 trademark registrations and 282 patent filings, along with 220 administrative licenses [1] Shareholding Structure - The major shareholder information indicates that 99.9797% of shares are held as unrestricted circulating shares, while 0.0203% are held as restricted or non-circulating shares [1]